Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.

导出 LinkOut

翻译打印收藏纠错

作者： Xiao-Yan,Zhao ^[1] ; Babu,Subramanyam ^[1] ; Nenad,Sarapa ^[2] ; Sven,Golfier ^[3] ; Harald,Dinter ^[1]

作者单位： Bayer Pharmaceuticals, Biologics Research, San Francisco, CA,USA. ^[1] Clinical Sciences, Whippany, NJ,USA. ^[2] Therapeutic Research Oncology, Berlin,Germany. ^[3]

关键词 7D9-MMAE Amatuximab Anetumab ravtansine Antibody (Ab)BMS-986148 DM1 or DM4: maytansinoid tubulin inhibitors DMOT4039A MDX-1204 Monomethyl auristatin E (MMAE)RG7787 SS1P antibody-drug conjugate (ADC)antigen cancer chimeric monoclonal antibody mesothelin recombinant immunotoxin (RIT)unconjugated antibody

DOI 10.2174/2212697X03666160218215744

PMID 27853672

发布时间 2022-03-31

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览39

Clinical cancer drugs

2016年3卷2期

76-86页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.

Clinical cancer drugs

相似文献

Clinical cancer drugs

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.

Clinical cancer drugs

相似文献

Clinical cancer drugs

相关期刊

检索历史清除